



20 May 2025

Sydney, Australia

## Corporate Update

---

### Highlights:

- Nyrada's largest CDI holder, Noxopharm Limited, is disposing of its entire holding in Nyrada (NOX Holding).
- 100 percent of the NOX Holding has been acquired by a syndicate of current and new Nyrada holders, including approximately 26 percent by Nyrada board and management.

---

**Nyrada Inc (ASX:NYR)**, a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibitors provides an update on its corporate structure.

In 2017, Noxopharm established Nyrada Inc. as a company focusing on innovative, first-in-class, small molecule drugs. Since then, Nyrada progressed to an ASX listing in 2020, and has become an independent clinical-stage company.

Noxopharm has today announced that it is disposing of its entire holding of Nyrada CHES Depository Interests (CDIs) through an off-market process: 33,373,245 CDIs at AU\$0.075 per CDI. This sale is expected to be completed over the coming days.

Approximately 26% of the NOX Holding CDIs have been acquired by members of the Nyrada Board with full participation by the company's management team.

**Nyrada Chair John Moore commented:** "The Board and I remain highly optimistic about the Company's future. Our lead drug candidate, NYR-BI03, is advancing well in its Phase I clinical trial and has shown exciting preclinical results across three significant and underserved conditions: ischemic stroke, traumatic brain injury (TBI), and myocardial ischemia-reperfusion injury. We see substantial opportunity ahead."

Canary Capital advised NOX on its sale of Nyrada securities.

-ENDS-



## About Nyrada Inc.

Nyrada Inc. is a biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection, positioning it for a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.*

### Investors and Media:

Dimitri Burshtein

T: 02 9498 3390

E: [info@nyrada.com](mailto:info@nyrada.com)

### Company Secretary:

David Franks

T: 02 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

## Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.